Compare BLCO & WLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLCO | WLK |
|---|---|---|
| Founded | 1853 | 1986 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 8.1B |
| IPO Year | 2022 | 2004 |
| Metric | BLCO | WLK |
|---|---|---|
| Price | $20.86 | $62.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 17 |
| Target Price | $21.93 | ★ $77.47 |
| AVG Volume (30 Days) | ★ 977.3K | 858.3K |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 3.46% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.75 |
| Revenue | $5,101,000,000.00 | ★ $11,170,000,000.00 |
| Revenue This Year | $7.83 | $3.95 |
| Revenue Next Year | $5.90 | $1.24 |
| P/E Ratio | ★ N/A | $82.20 |
| Revenue Growth | ★ 6.47 | N/A |
| 52 Week Low | $14.44 | $56.33 |
| 52 Week High | $21.40 | $124.23 |
| Indicator | BLCO | WLK |
|---|---|---|
| Relative Strength Index (RSI) | 67.50 | 43.80 |
| Support Level | $15.30 | $59.66 |
| Resistance Level | $21.38 | $79.22 |
| Average True Range (ATR) | 0.62 | 2.49 |
| MACD | 0.03 | -0.33 |
| Stochastic Oscillator | 71.81 | 15.74 |
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.
Westlake is a forward-integrated commodity chemicals firm based in Houston. It began as a single low-density polyethylene plant and expanded its capabilities to include ethylene, vinyl chloride monomers, and polyvinyl chloride over the next two decades. The acquisition of Axiall in 2016 made it a North American leader in chlor-alkali and PVC. Today, Westlake has two defined segments: performance and essential materials, and housing and infrastructure products. The HIP segment began operating in 2022 following a series of acquisitions in the building products space. The firm aims to maximize the value of its chemical production by integrating with the HIP segment, realizing the higher margins of finished commercial goods.